Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

The G Protein-Coupled Receptor RAI3 Is an Independent Prognostic Factor for Pancreatic Cancer Survival and Regulates Proliferation via STAT3 Phosphorylation.

Jahny E, Yang H, Liu B, Jahnke B, Lademann F, Knösel T, Rümmele P, Grützmann R, Aust DE, Pilarsky C, Denz A.

PLoS One. 2017 Jan 23;12(1):e0170390. doi: 10.1371/journal.pone.0170390. eCollection 2017.

2.

MicroRNA-126 overexpression rescues diabetes-induced impairment in efferocytosis of apoptotic cardiomyocytes.

Suresh Babu S, Thandavarayan RA, Joladarashi D, Jeyabal P, Krishnamurthy S, Bhimaraj A, Youker KA, Krishnamurthy P.

Sci Rep. 2016 Nov 9;6:36207. doi: 10.1038/srep36207.

3.

Platelet integrin α6β1 controls lung metastasis through direct binding to cancer cell-derived ADAM9.

Mammadova-Bach E, Zigrino P, Brucker C, Bourdon C, Freund M, De Arcangelis A, Abrams SI, Orend G, Gachet C, Mangin PH.

JCI Insight. 2016 Sep 8;1(14):e88245.

4.

ADAM9 Expression Is Associate with Glioma Tumor Grade and Histological Type, and Acts as a Prognostic Factor in Lower-Grade Gliomas.

Fan X, Wang Y, Zhang C, Liu L, Yang S, Wang Y, Liu X, Qian Z, Fang S, Qiao H, Jiang T.

Int J Mol Sci. 2016 Aug 26;17(9). pii: E1276. doi: 10.3390/ijms17091276.

5.

Influence of Immune Myeloid Cells on the Extracellular Matrix During Cancer Metastasis.

Jiang D, Lim SY.

Cancer Microenviron. 2016 Apr;9(1):45-61. doi: 10.1007/s12307-016-0181-6. Epub 2016 Mar 9. Review.

6.

Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy.

Sahin IH, Iacobuzio-Donahue CA, O'Reilly EM.

Expert Opin Ther Targets. 2016;20(3):341-59. doi: 10.1517/14728222.2016.1094057. Epub 2015 Oct 6. Review.

7.

The effect of disintegrin-metalloproteinase ADAM9 in gastric cancer progression.

Kim JM, Jeung HC, Rha SY, Yu EJ, Kim TS, Shin YK, Zhang X, Park KH, Park SW, Chung HC, Powis G.

Mol Cancer Ther. 2014 Dec;13(12):3074-85. doi: 10.1158/1535-7163.MCT-13-1001. Epub 2014 Oct 24.

8.
9.
10.

Regulators of epithelial mesenchymal transition in pancreatic cancer.

Hamada S, Satoh K, Masamune A, Shimosegawa T.

Front Physiol. 2012 Jul 10;3:254. doi: 10.3389/fphys.2012.00254. eCollection 2012.

11.

The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?

Duffy MJ, Mullooly M, O'Donovan N, Sukor S, Crown J, Pierce A, McGowan PM.

Clin Proteomics. 2011 Jun 9;8(1):9. doi: 10.1186/1559-0275-8-9.

12.

Molecular characteristics of pancreatic ductal adenocarcinoma.

Ottenhof NA, de Wilde RF, Maitra A, Hruban RH, Offerhaus GJ.

Patholog Res Int. 2011 Mar 27;2011:620601. doi: 10.4061/2011/620601.

13.

Inhibition of ADAM9 expression induces epithelial phenotypic alterations and sensitizes human prostate cancer cells to radiation and chemotherapy.

Josson S, Anderson CS, Sung SY, Johnstone PA, Kubo H, Hsieh CL, Arnold R, Gururajan M, Yates C, Chung LW.

Prostate. 2011 Feb 15;71(3):232-40. doi: 10.1002/pros.21237.

14.

Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer.

Roy R, Yang J, Moses MA.

J Clin Oncol. 2009 Nov 1;27(31):5287-97. doi: 10.1200/JCO.2009.23.5556. Epub 2009 Sep 8. Review.

15.

Loss of the metalloprotease ADAM9 leads to cone-rod dystrophy in humans and retinal degeneration in mice.

Parry DA, Toomes C, Bida L, Danciger M, Towns KV, McKibbin M, Jacobson SG, Logan CV, Ali M, Bond J, Chance R, Swendeman S, Daniele LL, Springell K, Adams M, Johnson CA, Booth AP, Jafri H, Rashid Y, Banin E, Strom TM, Farber DB, Sharon D, Blobel CP, Pugh EN Jr, Pierce EA, Inglehearn CF.

Am J Hum Genet. 2009 May;84(5):683-91. doi: 10.1016/j.ajhg.2009.04.005. Epub 2009 Apr 30.

16.

ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression.

Fritzsche FR, Wassermann K, Jung M, Tölle A, Kristiansen I, Lein M, Johannsen M, Dietel M, Jung K, Kristiansen G.

BMC Cancer. 2008 Jun 26;8:179. doi: 10.1186/1471-2407-8-179.

17.

Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis.

Pham NA, Schwock J, Iakovlev V, Pond G, Hedley DW, Tsao MS.

BMC Cancer. 2008 Feb 6;8:43. doi: 10.1186/1471-2407-8-43.

18.

ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer.

Valkovskaya N, Kayed H, Felix K, Hartmann D, Giese NA, Osinsky SP, Friess H, Kleeff J.

J Cell Mol Med. 2007 Sep-Oct;11(5):1162-74.

19.

New tumor-associated antigen SC6 in pancreatic cancer.

Liu MP, Guo XZ, Xu JH, Wang D, Li HY, Cui ZM, Zhao JJ, Ren LN.

World J Gastroenterol. 2005 Dec 28;11(48):7671-5.

Supplemental Content

Support Center